Fluorescence Guided Minimally-Invasive Resection Of Abdominal Paragangliomas Using Indocyanine Green
Launched by LEIDEN UNIVERSITY MEDICAL CENTER · Dec 1, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is investigating a new way to help surgeons find and remove abdominal paragangliomas, which are rare tumors, during minimally invasive surgery. The study uses a special imaging technique that involves a dye called indocyanine green (ICG). This dye helps make the tumors more visible during surgery, allowing doctors to treat them more effectively while making smaller cuts in the body.
To participate in this trial, patients should be diagnosed with an abdominal paraganglioma and be scheduled for a minimally invasive surgery to remove it. Unfortunately, those who are having open surgery won’t be eligible. If you join the trial, you can expect to undergo the surgery with the added benefit of this new imaging technique, which hopes to improve the chances of successfully identifying and removing the tumors. The trial is currently looking for participants, and both men and women between the ages of 65 and 74 are welcome to apply.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Diagnosed with abdominal paraganglioma and underwent minimally-invasive surgical resection
- Exclusion Criteria:
- • Open surgical procedures
About Leiden University Medical Center
Leiden University Medical Center (LUMC) is a prominent academic medical center located in the Netherlands, renowned for its commitment to advancing healthcare through innovative research and high-quality patient care. As a clinical trial sponsor, LUMC focuses on translating scientific discoveries into effective therapies, fostering collaborations between researchers, clinicians, and industry partners. The center is dedicated to conducting rigorous clinical studies across various medical fields, ensuring adherence to ethical standards and regulatory requirements while prioritizing patient safety and outcomes. Through its multidisciplinary approach, LUMC aims to contribute significantly to the understanding and treatment of complex health conditions, driving progress in personalized medicine and improving global health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Leiden, , Netherlands
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported